AURORA, ON, Jan. 18 /PRNewswire-FirstCall/ - Helix BioPharma Corp.
2007 will be a pivotal year for Helix and its L-DOS47 and Topical Interferon Alpha-2b programs, as stated in Helix’s 2006 Annual Report.
Helix’s experienced Board of Directors and Management have determined the need for the stated capital for 2007 in order to rapidly advance product development towards commercialization.
The proposed private placement is designed to achieve precisely this objective.
The earliest possible commercialization of Helix’s products is far more significant for shareholder value than any dilutive concerns.
The dissident has proposed no plan, strategy or direction to advance the Company.
Management urges all shareholders to continue to support your company and its emerging drug products.
------------------------------------------------------------------------- VOTE YOUR YELLOW HELIX PROXY NOW IF YOU HAVE ALREADY VOTED YOUR YELLOW HELIX PROXY, MANAGEMENT THANKS YOU FOR YOUR SUPPORT DO NOT VOTE A BLUE PROXY ----------- IF YOU HAVE ALREADY VOTED A BLUE PROXY, YOU CAN REVOKE IT BY SENDING IN A YELLOW HELIX PROXY NOW --- -------------------------------------------------------------------------
Also see Helix’s response to the dissident proxy circular dated January 10, 2007, filed at www.sedar.com and at www.helixbiopharma.com.
MAKE YOUR VOTE COUNT. PLEASE SIGN, DATE AND RETURN YOUR YELLOW PROXY BY JANUARY 19, 2007 AT 10:00 AM TORONTO TIME (EST) FOR YOUR VOTE TO COUNT.
A copy of Helix BioPharma’s current Annual Report and Management Information Circular for the January 23, 2007 meeting can be found on SEDAR at www.sedar.com, and at Helix’s website at www.helixbiopharma.com. Requests for a hard copy of the Annual Report or Management Information Circular can also be made to Georgeson.
Georgeson North American Toll Free Number: 1-866-288-9745 Outside North America Collect: +1-416-642-7018 (x) Toll Free - European: 00800 1020 1010 European Collect: +44 (0) 117 378 5993 (x) Australia; Austria; Belgium; Denmark; Finland; France; Germany; Hong Kong; Ireland; Israel; Italy; Netherlands; New Zealand; Norway; Spain; Sweden; Switzerland; Thailand; United Kingdom Please visit our website for regular updates at www.helixbiopharma.com
This document contains certain forward-looking information and statements regarding the Company’s beliefs, plans and objectives. Forward-looking information and statements are not historical facts but are predictions about the future and are inherently uncertain. Forward-looking information and statements can be identified by the use of forward-looking terminology such as “to be”, “to do”, “knows”, “is actually”, “pursing”, “must”, “believes”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, “would”, or “should” occur or be achieved, or comparable terminology referring to future events or results. The Company’s actual results could differ materially from a conclusion, forecast or projection in its forward-looking information and statements due to a variety of risks, uncertainties and other factors, including, without limitation: uncertainty as to the outcome of the January 23, 2007 shareholders meeting; uncertainty whether the Company will be able to complete any financing on the terms proposed or at all; liquidity risks, including the ability of the company to maintain a listing on a stock exchange, or the ability of the Company to secure listing on other stock exchanges; uncertainty whether any of the Company’s proposed drug products will be successfully developed or at all; the need for future clinical trials, the occurrence and success of which cannot be assured; the need for regulatory approvals, which approvals may not be obtained on acceptable terms or at all or may be withdrawn; research and development risks; uncertainty whether the L-DOS47 preclinical program will be completed as planned or at all; uncertainty whether an IND will be compiled or submitted for L-DOS47 as currently planned or at all, or if submitted, whether the Company will be permitted to undertake human testing; uncertainty whether the manufacturing process for L-DOS47 can be scaled-up successfully or at all; manufacturing risks and the need to manufacture to regulatory standards; the need for performance by buyers of the Company’s products; reliance by the Company on a few customers and a few suppliers; uncertainty regarding the Company’s ability to generate projected sales volumes and product prices; uncertainty of the size and existence of a market opportunity for, and market acceptance of, the Company’s products and those of its customers and licensees; the need to secure new contracts and new strategic relationships, which is not assured; intellectual property risks; marketing risks; uncertainty as to availability of raw materials on acceptable terms or at all; partnership/strategic alliance risks and in particular, the need for performance by the Company’s licensees, Lumera Corporation and Helsinn-Birex; product liability risks; the effect of competition; the risk of unknown side effects; the Company’s need for additional future capital, which may not be available in a timely manner or at all; exchange rate fluctuations; environmental risks; political risks; the risk of technical obsolescence; the possibility that the Company will pursue additional development projects or other business opportunities; the risk of unanticipated expenses; market volatility; the need to attract and retain key personnel; and other factors that are discussed or identified in the Company’s latest Annual Information Form filed on SEDAR at www.sedar.com any of which could cause actual results to vary materially from current results or the Company’s anticipated future results. Forward-looking statements are based on the assumptions, beliefs, opinions and expectations of the Company’s management at the time they are made, and the Company does not assume any obligation to update its forward-looking statement if those assumptions, beliefs, opinions or expectations, or other circumstances should change. For the reasons set forth above, investors should not place undue reliance on forward-looking statements. The Company does not assume any obligation to update any statement contained in this document.
Helix BioPharma Corp.
CONTACT: For more information and assistance in completing your YELLOWHelix proxy, please call Georgeson, Helix’s proxy solicitor: North Americantoll free number 1-866-288-9745, European(x) toll free number00800-1020-1010, Collect calls outside North America can be made at (416)642-7018 or +44(0)117-378-5993.
